Core Insights - Hillhouse Capital has completed the acquisition of Nanjing Mingjie Biomedical Testing Co., Ltd, marking another strategic move in the pharmaceutical outsourcing sector [1][4] - This acquisition follows Hillhouse's previous purchase of WuXi AppTec's subsidiaries, indicating a trend of divesting non-core assets by WuXi AppTec to focus on CRDMO models [3][7] Company Overview - Mingjie Biomedical, established in 2016 and headquartered in Nanjing, was previously a subsidiary of WuXi AppTec, which acquired 60% of its shares in 2020 to enhance its drug quality control and analysis capabilities [1][4] - The company provides a comprehensive drug quality research technology platform compliant with global regulatory standards, including FDA, EMA, and NMPA [2][5] Service Capabilities - Mingjie Biomedical's service offerings include small molecule drugs, biopharmaceuticals, complex formulations, excipients, packaging materials, cell and gene therapy products, and medical devices [2][5] - The company operates modern laboratories in Nanjing and Shanghai, adhering to cGMP standards, and offers services such as trace residue analysis, impurity separation and purification, structural identification, and compatibility studies [2][5] Regulatory Compliance - In 2023, both laboratories successfully passed FDA inspections and multiple CFDA audits, demonstrating a robust international quality management system and compliance capabilities [2][5]